Education
About Us
Working with TipRanks
Follow Us
Voyager Therapeutics (VYGR)
NASDAQ:VYGR
VYGR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.80 - $10.66
Previous CloseN/A
Volume91.62K
Average Volume (3M)356.92K
Market Cap
$216.86M
Enterprise Value$38.42M
Total Cash (Recent Filing)$46.86M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)5.5
Beta0.95
Next Earnings
May 13, 2025EPS Estimate
-0.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.72
Shares Outstanding54,625,587
10 Day Avg. Volume330,467
30 Day Avg. Volume356,923
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.39
Price to Cash Flow (P/CF)-2.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.18
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.16
Enterprise Value/Ebitda2.72
Forecast
1Y Price Target
$16.20Price Target Upside308.06% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
---
Bulls Say, Bears Say
Bulls Say
Drug DevelopmentVoyager and NBIX have selected lead development candidates in three partnered programs, with INDs expected for the GBA and FXN programs.
Financial StabilityVYGR reported cash of $332MM, sufficient to fund operations to mid-2027.
Bears Say
Clinical Development RisksVYGR announced discontinuation of the development of its pre-clinical SOD1 silencing gene therapy candidate for ALS due to neurotoxicity at high doses.
---
Ownership Overview
2.35% Insiders
13.29% Mutual Funds
30.19% Other Institutional Investors
43.66% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
VYGR FAQ
What was Voyager Therapeutics’s price range in the past 12 months?
Voyager Therapeutics lowest stock price was $3.80 and its highest was $10.66 in the past 12 months.
What is Voyager Therapeutics’s market cap?
Voyager Therapeutics’s market cap is $216.86M.
When is Voyager Therapeutics’s upcoming earnings report date?
Voyager Therapeutics’s upcoming earnings report date is May 13, 2025 which is in 61 days.
How were Voyager Therapeutics’s earnings last quarter?
Voyager Therapeutics released its earnings results on Mar 11, 2025. The company reported -$0.59 earnings per share for the quarter, missing the consensus estimate of -$0.367 by -$0.223.
Is Voyager Therapeutics overvalued?
According to Wall Street analysts Voyager Therapeutics’s price is currently Undervalued.
Does Voyager Therapeutics pay dividends?
Voyager Therapeutics does not currently pay dividends.
What is Voyager Therapeutics’s EPS estimate?
Voyager Therapeutics’s EPS estimate is -0.42.
How many shares outstanding does Voyager Therapeutics have?
Voyager Therapeutics has 54,625,587 shares outstanding.
What happened to Voyager Therapeutics’s price movement after its last earnings report?
Voyager Therapeutics reported an EPS of -$0.59 in its last earnings report, missing expectations of -$0.367. Following the earnings report the stock price went up 2.267%.
Which hedge fund is a major shareholder of Voyager Therapeutics?
Currently, no hedge funds are holding shares in VYGR
---
Voyager Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.20 (308.06% Upside)
$16.20 (308.06% Upside)
Blogger Sentiment
Bullish
VYGR Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 278.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $176.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.3%
Last 30 Days ▼ 5.5%
Last 30 Days ▼ 5.5%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-56.18%
12-Months-Change
Fundamentals
Return on Equity
10.22%
Trailing 12-Months
Asset Growth
44.59%
Trailing 12-Months
Company Description
Voyager Therapeutics
Voyager Therapeutics, Inc. operates as a clinical-stage gene therapy company, which develops treatments for patients suffering from central nervous system. Its pipeline of gene theraphy programs include VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guangping Gao, Mark A. Kay, Krystof Bankiewicz and Phillip Zamore in June 2013 and is headquartered in Cambridge, MA.
---
VYGR Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a positive outlook with significant advancements and strong financial positioning. Despite a setback in the SOD1 silencing program, the progress in tau-targeting therapies and potential substantial milestone payments from partnerships highlight a promising future.Read More>---
VYGR Stock 12 Month Forecast
Average Price Target
$16.20
▲(308.06% Upside)
Technical Analysis
Sangamo Biosciences
―
Bluebird Bio
―
Editas Medicine
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Best Analysts Covering VYGR
1 Year
1 Year Success Rate
9/20 ratings generated profit
1 Year Average Return
-3.35%
reiterated a buy rating 4 months ago
Copying Jack Allen's trades and holding each position for 1 Year would result in 45.00% of your transactions generating a profit, with an average return of -3.35% per trade.
---